Department of Thoracic Surgery, Binzhou Medical University Hospital, No. 661 Huanghe 2nd Road, Binzhou, 256603, Shandong, People's Republic of China.
Department of Neonatal Intensive Care Unit, Binzhou People's Hospital, No. 515 Huanghe 7th Road, Binzhou, 256603, Shandong, People's Republic of China.
World J Surg Oncol. 2020 Jun 27;18(1):144. doi: 10.1186/s12957-020-01917-5.
The prognosis of adenocarcinoma of the esophagogastric junction (AEG) is poor. Understanding the postoperative recurrence pattern of AEG is helpful to verify the effectiveness of treatment and optimize subsequent treatment, so as to improve prognosis.
This single-center retrospective study included patients with stage III AEG who underwent surgical treatment between January 2009 and December 2016. According to the different postoperative treatment arm, patients were divided into surgery and surgery plus chemotherapy groups. Recurrence-free survival was used as the outcome to compare the recurrence site and pattern between the groups.
In total, were 306 patients enrolled, 123 in the surgery group and 183 in the surgery plus chemotherapy group. During follow-up (median 17.1 months) of 24 months after surgery, 62.0% of patients had tumor recurrence. The overall recurrence rates in the surgery and surgery plus chemotherapy groups were 86.9% and 77.0%, respectively. The recurrence patterns of both groups were mainly distant metastasis. Postoperative chemotherapy reduced the incidence of hematogenous dissemination from 51.2 to 42.0%. Multivariate Cox analysis showed that the pN stage increased the risk of recurrence, while surgery plus chemotherapy reduced the risk.
Patients with AEG have a risk of hematogenous dissemination after surgery. Postoperative treatment arm and pN stage were independent risk factors in patients with AEG. Surgery plus chemotherapy can improve recurrence-free survival and reduce distant metastasis, but they do not have a beneficial role in controlling local recurrence.
食管胃结合部腺癌(AEG)的预后较差。了解 AEG 的术后复发模式有助于验证治疗效果并优化后续治疗,从而改善预后。
这是一项单中心回顾性研究,纳入了 2009 年 1 月至 2016 年 12 月期间接受手术治疗的 III 期 AEG 患者。根据术后治疗方案的不同,将患者分为手术组和手术加化疗组。无复发生存期作为观察终点,用于比较两组的复发部位和模式。
共纳入 306 例患者,手术组 123 例,手术加化疗组 183 例。术后 24 个月的中位随访时间为 17.1 个月,62.0%的患者出现肿瘤复发。手术组和手术加化疗组的总复发率分别为 86.9%和 77.0%。两组的复发模式主要为远处转移。术后化疗使血行播散的发生率从 51.2%降至 42.0%。多因素 Cox 分析显示,pN 分期增加了复发风险,而手术加化疗降低了复发风险。
AEG 患者术后存在血行播散的风险。术后治疗方案和 pN 分期是 AEG 患者的独立危险因素。手术加化疗可以提高无复发生存率,降低远处转移率,但对控制局部复发无益处。